LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)

Xiuning Le, J. Patel, Elaine Shum, R.E. Sanborn, Christina S. Baik, Catherine A. Shu, Chul Kim, Mary Fidler, R. Hall, N. Hanna, Nisha Mohindra, Joshua K. Sabari, Simon Heeke, Mike Hernández, Jhanelle E. Gray, John V. Heymach, Andreas Saltos